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Regular insulin can reduce hyperglycemia when directly added to total parenteral nutrition
(TPN) solutions. Insulin is not routinely added to all TPN solutions. For patients who require
insulin prior to the initiation of TPN supplement, one-third to one-half of the usual total
daily dose can be added to the TPN bag as regular human insulin. However, an incorrect
dose or an interaction between insulin and the TPN bag material may affect blood sugar
control in clinical practice. Therefore, it is important to quantitatively determine the final
dose of insulin in the TPN bag. High performance liquid chromatography is a very powerful
technique for determining the purity of proteins. The goal of this study was to use high-
performance liquid chromatography to perform quantitative analysis of insulin in a TPN
bag. The analysis was performed under different light conditions (UV, fluorescent, and
darkness) and different temperatures (25C and 2e8C). The results show that adsorption
of insulin on an ethylene vinyl acetate TPN bag is significantly higher than that on glass.
Based on the results, it is evident that regular insulin should be administered separately
from TPN to reduce cost and eliminate wasteful disposal of TPN solutions.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Traditionally, people who are unable to eat on their own are
tube fed via the mouth. This method of delivering nutrients
directly to the stomach is referred to as enteral nutrition. In
1968, Dudrick et al [1] investigated the delivery of smallrmacy, Kaohsiung Medic
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/licenses/by-nc-nd/4.0/).volumes of highly concentrated nutrients through the supe-
rior vena cava (fast blood flow, concentrated nutrients diluted
by blood). Since then, a new formof acquiring nutrients, called
total parenteral nutrition (TPN), has been introduced [2]. Pre-
vious studies have shown that up to 50% of hospitalized pa-
tients are malnourished. Supplemental nutrients help
patients deal with stress and can mitigate the complicationsal University Hospital, Number 100, Shihcyuan 1st Road, Sanmin
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surgery [3e5]. Thus, the importance of supplementary nutri-
tion for patients under stress is obvious.
TPN primarily consists of nutrients, micronutrients, and
other individual components. Insulin is often included in TPN
to control blood sugar levels because hyperglycemia is the
most common complication associated with TPN. The occur-
rence of hyperglycemia in patients receiving TPN can be as
high as 47%. Typically, insulin is administered to control blood
sugar levels and achieve euglycemia. Stable euglycemia re-
duces the complications associated with blood sugar moni-
toring and insulin administration, thus reducing the burden
on health care providers [6e8].
Regular insulin can reduce hyperglycemia when it is
directly added to the TPN solution [9]. However, hypoglyce-
mia may occur when insulin is continually administered.
Hypoglycemia is less likely to result from a decrease in the
fluid rate or inadvertent interruption of TPN fluid if insulin is
added directly to the fluid rather than given by subcutaneous
injection [9,10]. Insulin is not routinely added to all TPN so-
lutions. For patients who require insulin prior to the initia-
tion of TPN, one-third to one-half of the usual total daily dose
can be added to the TPN bag as regular human insulin.
Depending on blood glucose levels, additional subcutaneous
insulin may be administered. Thus, precise dosages of insulin
in the TPN solution can help health-care providers control
blood sugar levels better. However, under- or overestimated
doses of insulin in the TPN bag, or interactions between in-
sulin and the TPN bag material may affect blood sugar con-
trol significantly. Therefore, it is important to quantitatively
determine the precise dose of insulin to be added to the TPN
solution.
In 1951, Ferrebee et al [11] suggested that insulin can be
adsorbed on a glass infusion container. Since then, insulin has
been found to be adsorbed on polyvinylchloride, polyethylene,
and silicone-treated glassware infusion sets. Many factors
such as purity and source of TPN solution, TPN package ma-
terial, and insulin itself have changed over the past decades.
For example, the purity of insulin has increased by the use of
recombinant DNA technology to produce human insulin. The
TPN package is now made of nonpolyvinylchloride material
such as ethylene vinyl acetate (EVA).
Concentration analyses of insulin in the TPN solution have
revealed several factors including the effect of the infusion
solution, packaging materials, temperature, and light expo-
sure on insulin [12e14]. From a previous research, insulin was
tagged with I125 and then added to an EVA bag containing
amino acid, dextrose, electrolytes, heparin, and vitamin. The
availability of human insulin was higher than that reported in
the literature [14]. However, this research also found that the
amount of insulin that binds to the infusion material was
much greater than the amount that binds to the components
in the TPN solution. Adsorptionwas related to the surface area
of the bag. For example, if the same amount of insulin were
added to bags with different volumes (500 mL and 1000 mL),
adsorption would be greater for bags with greater volumes
[14]. In addition, a previous research also indicated that
different packagingmaterials had different insulin adsorption
capacities. Soda and silicon-soda glassmaterials, as compared
to plastic materials, have higher insulin adsorption capacity.Sodium chloride, potassium chloride, and water-soluble vi-
tamins do not seem to affect insulin adsorption on these
materials [12]. Furthermore, infusion tubing materials can
contribute to insulin adsorption. In a study, it was observed
that a glass container resulted in 52% insulin adsorption and
that plastic tubing contributed another 55.4%, resulting in
total insulin adsorption of >78.8% [13].
The effect of temperature on insulin adsorption in the TPN
solution is subtle. Research on the effect of temperature on
insulin adsorption in a dialysis bag indicated that regular in-
sulin shows greater adsorption at a high temperature (37C)
than at a low temperature (24C); however, adsorption ca-
pacity decreases as the insulin dosage increases [15]. To the
best of our knowledge, no study has addressed the effect of
light on insulin adsorption in a TPN bag. Most TPN finished
products are sealed with a tin foil after preparation and, thus,
are not exposed to light. Unfortunately, once sealed, it be-
comes difficult to check TPN end products for impurities and
identify insulin levels of the patient in clinical practice. This
sealing method is currently not implemented in our
institution.
Many nonimmune and immune methods have been re-
ported for the determination of insulin in in vivo or in vitro
media, including radioimmunoassay [16], enzyme immuno-
assay [17,18], capillary electrophoresis [19], luminescent
immunoassay [20], and high performance liquid chromatog-
raphy (HPLC) [21e24]. HPLC has widely been used for human
insulin detection since 1986 and has been applied to quanti-
tative analyses of insulin in various preparations [25].
Despite various factors, such as container material, light
exposure time, and temperature, which have been reported to
possibly affect insulin in TPN, in Taiwan, studies to quanti-
tatively determine the final dose of insulin in a TPN bag are
limited. Therefore, the goal of this experiment is to determine
whether the insulin in a TPN bag is affected by the package
material, light exposure time, and temperature, using HPLC
analysis.2. Methods
In this study, we primarily used HPLC to analyze the insulin
solution for injection into an EVA TPN bag. Quantitative ana-
lyses of insulin were performed under different temperature
and light exposure conditions.
2.1. Insulin samples
Several insulin products used in our hospital were evaluated
and compared. Rapid-acting clear insulin Actrapid HM® (1000
U/10 mL/vial) (Novo Nordisk A/S/Kalundborg, Denmark) was
selected for this study. Prior to performing the quantitative
analysis, each sample of rapid-acting clear insulin Actrapid
HM (1000 U/10 mL/vial) was maintained at 2e8C.
Fifty international units of Actrapid were added to a TPN
bag preloaded with 50 mL of water. A 500 mL Baxter EVA TPN
bag was used in this study. Fifty international units of insulin
were placed in a general glass tube. The procedure was
checked by two pharmacists (an operator and a monitor). The
contents were thoroughly mixed, and after different
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performed using HPLC.
2.2. Study procedures
In this study, we used a UV spectrophotometer to scan the
insulin absorption spectrum to determine the appropriate
wavelength. This allowed us to establish the insulin standard
curve for Actrapid. Then, we tested intra- and interday
precision.
We placed the TPN bag and glass tube in different temper-
ature environments, including room temperature (25C), and
under refrigeration (2e8C). We performed HPLC quantitative
analysiswith different sampling times (0 hours, 0.25 hours, 0.5
hours, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, 24 hours, 36
hours, 48 hours, and 72 hours). In addition, we prepared the
EVA TPN bag and glass tube in different illumination environ-
ments, including a fluorescent tube and a UV lamp. As before,
we performedHPLCquantitative analysiswith sampling times
of 0 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8
hours, 16 hours, 24 hours, 36 hours, 48 hours, and 72 hours.
2.3. Chemicals and equipment
We used the Agilent 1100 Series HPLC System, an Agilent 8453
UV spectrophotometer, and an Intersil ODS-2 C18 column
(5 mm, 150 mm  4.6 mm) (GL Science/Shinjuku-ku, Tokyo,
Japan). HPLC-grade methanol was purchased from Merck
(Darmstadt, Germany), HPLC-grade acetonitrile was pur-
chased from Fisher (Waltham, Massachusetts, USA),
analytical-grade trifluoroacetic acid (>99%) was purchased
fromAcros (Geel, Belgium), and injectionwaterwas purchased
from Nang Kuang Pharmaceuticals (Tainan city, Taiwan).
The sample withdrawn from the TPN bag was then
analyzed using an HPLC method (wavelength 214 nm; pres-
sure 102 bar) modified from a previous study [26]. The mobile
phase was a mixture of acetonitrile, water, and trifluoroacetic
acid in the ratio 500:500:1. The flow, run time, and sample
volume were 1 mL/min, 10 minutes, and 20 mL, respectively.
Prior to the experiment, the mobile phase was degassed for 30
minutes. At the end of the experiment, the column was
washed with methanol for 30 minutes and with water for
another 30 minutes. We used 0.1700 g of methylparaben dis-
solved in 2.0 L of 0.01MHCl as the internal standard. Each data
point represented the average of three determinations.
2.4. Outcomes
TPN products were observed under different temperature
(25C and 2e8C) and light exposure (UV, fluorescent, and
darkness) conditions. The percentage of insulin adsorption
was calculated using mAU of sampling time 0 as the denom-
inator andmAU of different sampling times as the numerator.
The percentage change of insulin adsorption was plotted and
compared with that of the control group (glass material).
2.5. Statistical analysis
We used analysis of variance to analyze differences in per-
centage adsorption of insulin at different times underdifferent conditions, including different materials (TPN bag or
glass), different temperatures (25C and 2e8C), and different
light exposure conditions (UV, fluorescent, and darkness).
Statistical significance was defined as a two-sided p value of
<0.05. All statistical analyses were performed using Software
package SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).3. Results and discussion
Clinically, if the TPN solution was to be used over the
weekend, the solution would be prepared 1 day earlier and
stored under refrigeration (2e8C). In this study, the known
factors (variables) affecting insulin adsorption in the TPN
solution were temperature, time, and light exposure. The
present study investigated the effect of the container mate-
rial on insulin adsorption.We found that for all variables, the
EVA TPN bag used by our institution had a greater effect on
insulin adsorption than the glass container. The HPLC pro-
files of insulin in glass and TPN bag at 25C and under
darkness are shown in Fig. 1. The HPLC profiles of the two
materials were strikingly different. The result showed that
the glass container did not adsorb insulin (Fig. 1A) but the
TPN bag did (Fig. 1B).
3.1. Temperature and container material
Fig. 2 illustrates the positive correlation of time to insulin
adsorption on the EVA bag. The same results were observed
under both room temperature and refrigerated conditions. In
addition, for the same conditions, absorption by the plastic
bag was greater than that by the glass container. At 25C,
without light exposure for 24 hours, insulin adsorption on the
EVA bag was 62.71% and that on the glass material was 6.34%,
with a significant p value of <0.05.
3.2. Light exposure
Under darkness, insulin adsorption on the EVA bag at 25C
was 62.71%. Although the value is greater than that for
refrigerated adsorption (46.51%), the difference is not statis-
tically significant. As shown in Fig. 2, adsorption reached the
maximum value after 36 hours.
Under the same temperature, but different light exposure
conditions (Fig. 3), adsorption on the plastic bag was greater
than that on the glass container. At 25C, insulin adsorption
on the EVA bagwas 60.52%,whereas that on the glassmaterial
was 5.43%. The p value was <0.05, which is statistically sig-
nificant. Similar results were observed at 25C under dark-
ness. However, if the same materials were used, the light
exposure difference would have been statistically
insignificant.
3.3. Light sources
Under different light sources, insulin adsorption on the EVA
bag is still greater than that on the glass material (Fig. 4). At
25C, under UV light exposure, insulin adsorption on the EVA
bag and that on the glass material was 74.12% and 13.34%,
respectively. At 25C, under darkness, insulin adsorption on
Fig. 1 e (A) Chromatogram of insulin in glass at 25C and under darkness. (B) Chromatogram of insulin in a plastic bag at
25C and under darkness.
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Fig. 2 e Adsorption of insulin on different materials and at
different temperatures under darkness: glass compared to
plastic bag at 25C, p < 0.001; glass compared to plastic bag
at 2e8C, p < 0.001.
Fig. 4 e Adsorption of insulin on different materials, at
different temperatures, and under light exposure
condition: glass exposed to UV light compared to plastic
bag at 25C, p < 0.001; glass compared to plastic bag at 25C
and under darkness, p < 0.001; glass compared to plastic
bag at 25C and under exposure to fluorescent light,
p < 0.001; glass compared to plastic bag at 2e8C and under
darkness, p ¼ 0.004.
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12.31%, respectively. The p values were <0.05 and were thus
statistically significant.
Insulin adsorption on infusion materials can be prevented
or reduced by serum albumin. In addition, heparin and
dextran have been reported to reduce insulin adsorption but
with subtle results. Albumin reduction of insulin adsorption
has the greatest effect at a concentration of approximately
0.1%. However, the addition of albumin has economic and
potential contamination issues; consequently, it is not
implemented at our institution.
Clinically, insulin administration can be categorized into
the following methods: (1) insulin administration in a TPN
solution; (2) direct intramuscular administration; (3)Fig. 3 e Adsorption of insulin on different materials and
under light exposure condition at 25C: glass exposed to a
fluorescent light compared to plastic bag exposed to a
fluorescent light, p ¼ 0.001; glass under darkness
compared to plastic bag under darkness, p ¼ 0.005.coadministration with TPN and intramuscular methods, and
(4) continuous insulin infusion.When insulin is administrated
in TPN, the insulin dose must be modified after the blood
sugar level has been stabilized, in order to prevent hypogly-
cemia. When this occurs, it is possible that all of the prepared
TPN will be discarded. A previous study has indicated that
separate insulin infusion can save 7.3 L of TPN solution per
patient, which represents a saving of approximately $395.
Patients utilizing separate insulin infusion can have their
blood sugar levelmaintained at approximately 100e250mg/dL
in ~73% of 636 blood draws; blood sugar levels never fall below
50 mg/dL. Benefits of separate insulin infusion also include
reduction of catheter sepsis.
3.4. Conclusion
In this study, HPLC was used to perform quantitative analysis
of insulin adsorption on different materials, i.e., EVP TPN bag
and glass, under different light and temperature conditions.
The results indicate a significant difference (p < 0.05) in the
adsorption rates. Adsorption of insulin on EVA bags was
greater than that on glass under different light (UV, fluores-
cent, and darkness) and temperature (25C and 2e8C) con-
ditions. Thus, it is reasonable to conclude that regular insulin
should be administered separately from TPN to reduce cost
and eliminate wasteful disposal of TPN solutions.
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